Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 152020 Cardiac Repolarisation Trial
NCT05508776Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JW1601 in atopic dermatitis (AD) (4 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Placebo-corrected change from baseline of QT interval corrected using Fridericia's formula at 24 hours. Started Sep 2022; status: completed.
02
Drugs
JW1601
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05508776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508776.